Breast cancer is the most common cancer in women. In 2004, estimates were that about 215,990 women and approximately 1,500 men in the US would be diagnosed with invasive breast cancer. Surgery and radiotherapy, either alone or combined, remain the most effective techniques to treat cancer. Surgical procedures have been clearly defined by several randomised clinical trials that demonstrated equivalent survival with breast-conservation surgery combined with radiotherapy versus mastectomy. In the last few years, in order to avoid the risk of lymphoedema caused by axillary dissection, in patients free from axillary lymph node metastases sentinel lymph node biopsy has been widely accepted as a standard of care. The use of whole-breast irradiation with or without a boost is the standard of care at present. The value of adding nodal irradiation to the breast irradiation is unproven. Local control is influenced not only by treatment modalities but also by screening programmes, allowing the possibility of identifying smaller and smaller lesions. Nowadays, local control for breast cancer is a fundamental part of treatment. The surgical approach is tailored towards conservation of the breast and good-looking cosmesis, while radiotherapy is tailored towards reduction of treated volume to reduce damage and to spare time and cost.
At the beginning of the third millennium, one in three EU citizens will have to deal with cancer in the course of his or her life. Worldwide, the estimated number of new cancer cases is expected to rise from 10 million in 2000 to 15 million by 2020. Currently, cancer is the cause of 12% of all deaths worldwide. In the EU, over 1.5 million new cancer cases are diagnosed every year, and over 920,000 people die of cancer, the most common cancer sites being the breast and the prostate. About 90% of cured patients recover because of locoregional control; 18% of all patients die because of a primary tumour without metastases. This means that local treatment is as important as systemic therapy.
Breast cancer is the most common cancer in women. In 2004 it was estimated that 215,990 women and 1,500 men in the US would be diagnosed with invasive breast cancer. In the last decade there has been a 21% decrease in age-adjusted mortality from breast cancer. 1 The decline in mortality has been attributed to early detection of the disease and to the use of aggressive multimodality treatment leading to improved clinical outcomes.
Locoregional Treatment
Surgery and radiotherapy, either alone or combined, remain the most effective techniques to treat cancer. More than half of all cancer patients are now treated by radiation therapy (RT) thanks to the technical progress made with irradiation equipment over the last 10 years. Today a woman with early-stage breast cancer can be approached with the assumption that her breast can be spared and that therapy will be provided in a tailored and integrated fashion.
Breast Surgery
Surgical procedures have been clearly defined by several randomised clinical trials that demonstrated equivalent survival with breast conservation surgery combined with radiotherapy versus mastectomy.
In a study of 701 randomised women, Veronesi et al. reported that after a follow-up of 20 years, 30 women in the group who underwent breast conservation therapy had a recurrence of tumour in the same breast, whereas eight women in the radical mastectomy group had local recurrences (p<0.001). The crude cumulative incidence of these events was 8.8 and 2.3%, respectively, after 20 years. By contrast, there was no significant difference between the two groups in the rates of contralateral breast carcinomas, distant metastases or second primary cancers. After a median follow-up of 20 years, the rate of death from all causes was 41.7% in the group who underwent breast conservation surgery and 41.2% in the radical mastectomy group (p=1). The rate of death from breast cancer was 26.1 and 24.3%, respectively (p=0.8). Breast Cancer
locoregional therapy, demonstrated that the use of radiation after surgery significantly decreased the 15-year risk of breast cancer mortality for most women treated for breast cancer. Specifically, in the trials that investigated radiation use after breast conservation surgery, the meta-analysis demonstrated that radiation provided a 70% proportional reduction in the risk of locoregional recurrence (LRR). For patients with lymph-node-negative disease treated with breast conservation, radiation reduced the risk of LRR from 29 to 10%, and for those with lymph-node-positive disease, the LRR rates were reduced from 47 to 13%. After 15 years, these benefits translated into a 5% (lymph-node-negative) and 7% (lymph-nodepositive) absolute reduction in breast cancer mortality. The survival benefits did not become evident until after five years of follow-up. 4 However, there are some situations in which breast-conserving surgery is not possible (multicentric breast cancer, diffuse malignant microcalcification, prior breast irradiation, pregnancy or active collagen disease). Another common reason for performing mastectomy for early-stage breast cancer can be the tumour size relative to breast size, because excision to a clear margin could leave a significant deficit in breast volume or distort the shape of the breast in such a way that a better cosmetic outcome could be achieved by skin-sparing mastectomy and reconstruction. In order to avoid mastectomy, it is possible to prescribe pre-operative (neoadjuvant) chemotherapy. This approach permitted a 60% rate of breast-conservation therapy in women who would otherwise have required mastectomy. 5 In addition, patients who received neoadjuvant chemotherapy after mastectomy are at risk of LRR related to both the initial extent of disease, defined by clinical staging, and the residual post-chemotherapy pathological extent of disease. Within this cohort, the use of RT was also associated with improved disease-specific and overall survival. 7 Patients with lymph-nodepositive disease who did not undergo neoadjuvant chemotherapy were shown to derive benefits from the use of adjuvant radiation after mastectomy as well. In this cohort, the use of radiotherapy reduced LRR from 29 to 8% and improved the 15-year breast cancer mortality rate by 5%. Locoregional Therapy in Breast Cancer
reported 39.2% local failure without irradiation compared with 14.3% with irradiation. 12 The value of adding nodal irradiation to the breast irradiation is unproven. 13 Local control is influenced not only by treatment modalities but also by screening programmes (allowing the possibility of identifying smaller and smaller lesions). In fact, in our experience the cumulative incidence of breast relapse is 4.8%, but, considering two subpopulations (pre-and post-1991) that are significant in order to distinguish screening modalities, we found a breast relapse incidence of 10.3 and 2.1%, respectively (Fisher exact test p=0.0001) (see Figure 1 ).
Alternative methods of delivering radiation treatment after breast conservation surgery include accelerated WBI and accelerated partial breast irradiation (APBI). Hypofractionation is attractive for WBI or partial breast irradiation because it allows treatment to be given with fewer fractions in a shorter period of time and at a lower cost. A number of cohort studies suggest that hypofractionation may be given to the whole breast safely and with good local control. Recent randomised trials have confirmed that hypofractioned WBI is equivalent to conventional WBI in terms of LRR and cosmetic outcome. [14] [15] [16] In women treated with conservative breast surgery, whether or not followed by radiotherapy, at least three-quarters of ipsilateral tumour relapses occur in the vicinity of the primary tumour [17] [18] [19] 
